$0.067
-0.033 (-49.55%)Zum Schluss
DVLT-News
DVLT-Events
Datavault AI Plans to Acquire 19.9% Stake in DataMEDS
Datavault AI (DVLT) announced that it has entered into a non-binding letter of intent to acquire a 19.9% equity interest in DataMEDS AI (MEDS) in consideration of an expansion of its existing technology license with DataMEDS. The proposed transaction is subject to completion of due diligence and negotiation of definitive agreements and will be subject to customary closing conditions for a transaction of this nature. The proposed transaction is structured to provide Datavault AI with the opportunity to obtain an equity interest in DataMEDS while preserving ownership of its underlying intellectual property. In exchange for expanding its existing technology license, Datavault AI expects to receive a 19.9% equity interest in DataMEDS on a fully diluted basis, with the opportunity to participate in potential royalty revenue generated through commercialization of the licensed technologies, subject to negotiation and execution of definitive agreements. DataMEDS would assume responsibility for commercialization costs, allowing Datavault AI to leverage its existing intellectual property through a capital-efficient model. This announcement comes following the U.S. Food and Drug Administration's recent guidance regarding regulatory considerations for prescription drug use-related software. Through the proposed transaction, DataMEDS seeks to expand its healthcare technology capabilities by entering into arrangements with several parties, including Datavault AI, EOS Technology Holdings, Scilex Holding Company (SCLX), HealthBridge Advisors, and REBOOT Health AI. The proposed agreement would build on the DataMEDS PharmacyChain platform and EinsteinRx AI capabilities, which already operate under an existing license from Datavault AI. Datavault AI would contribute an expanded, exclusive license to its Datavault AI Health capabilities, which are designed to support patient-controlled health data access, monetization, and tokenization across pharmacy, laboratory, wearable, and broader commercial healthcare environments. Datavault AI would retain ownership of its underlying intellectual property, with DataMEDS assuming responsibility for the costs associated with commercializing the licensed technologies. The LOI also contemplates that Datavault AI will have the right to designate one director to the DataMEDS board following the closing of the proposed transaction. The LOI is nonbinding with respect to completion of the proposed transaction, and the parties are under no obligation to consummate the proposed transaction absent definitive agreements. The LOI may be terminated by the parties under certain circumstances, including as a result of due diligence. Relevant Datavault AI foundational patent records include U.S. Patent No. 12,100,025, Platform for Management of User Data; U.S. Patent No. 12,596,819, Method and System for Data Valuation and Secure Commercial Monetization Platform; and U.S. Patent Application Publication No. 2022/0188925, Data Futures Platform. These DataVault AI patents relate to data management, valuation and monetization technologies. The specific patents and applications covered by the proposed healthcare license remain subject to confirmation in the definitive license schedule. The expanded license is intended to support patient-controlled health data access, management, valuation, monetization and tokenization across pharmacy, laboratory, wearable and other commercial healthcare settings.
DataMEDS Enters into Letter of Intent with Datavault AI
DataMEDS AI has entered into an amended and restated non-binding letter of intent dated October 19 with Datavault AI, Data Health Partners' wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Scilex Holding Company and HealthBridge Advisors. EOS and Scilex each own a portion of the Quality of Life Peace of Mind intellectual property portfolio that is expected to be reunited through this transaction. DataMEDS' subsidiary Corexa Health has an established distribution nationwide network of 6,500 independent pharmacies. The Amended and Restated LOI supersedes and replaces the Amended and Restated Letter of Intent dated July 29, which expired on September 30, 2026. The addition of DHP reflects the progress DataMEDS has made in building its healthcare ecosystem, including the recent launch of the Health Lives Here mobile application together with Tollo Health in partnership with NFL Alumni Health, the acquisition of Helomics Corporation, a cancer diagnostics artificial intelligence laboratory certified under the Clinical Laboratory Improvement Amendments, and the license of key intellectual property from DHP's subsidiary REBOOT that enables the establishment, progress towards, and achievement of preset near and long-term goals as it relates to the use of GLP-1 receptor agonist-based medications. The transaction is expected to close in the fourth quarter of 2026. A majority of DataMEDS shareholders have approved the draft definitive agreements associated with this proposed transaction, subject to satisfactory completion of due diligence by management. Technologies Proposed to Be Added to the DataMEDS Healthcare Stack: Expand DataMEDS' existing PharmacyChain license with Datavault AI to exclusively include Datavault AI healthcare related intellectual property, subject to specified carve-outs for intellectual property already licensed to Vivasor, Inc. in medical imagery, Scilex within the field of use of Biotechnology and Quantum Scan Holdings, Inc. in diagnostics. Acquire QOLPOM intellectual property from EOS that enables biometric confirmation that the named patient receives home drug delivery, including by unmanned aerial drone; Acquire QOLPOM intellectual property from Scilex that enables wearables-driven biometric confirmation of pharmacodynamic drug effect; Exclusively license Data Health Partners' intellectual property related to data-driven patient outcomes, goal setting, goal progression and goal achievement in connection with home and aerial drone medication delivery; and Acquire a controlling interest in Tollo Health from HealthBridge Advisors. Tollo Health manufactures medical foods for GLP-1-associated muscle loss, acute viral infections and chronic viral infection syndromes, and dietary supplements with ingredients associated with specific biological pathways. Tollo also brings with it proprietary consumer engagement technology through the Health Lives Here mobile application it is already with DataMEDS upon, and NFL Alumni Health-driven marketing channels. The transaction is expected to close in the fourth quarter of 2026, and remains subject to the execution of definitive agreements, due diligence, a fairness opinion, a DataMEDS outstanding liabilities threshold, Nasdaq requirements, including change-of-control review under Listing Rule 5110(a)) and other customary conditions. No assurance can be given that definitive agreements will be executed or that the transaction will close.
Datavault AI Appoints Jeffrey Tirman to Board of Directors
Datavault AI announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Tirman was designated by NYIAX in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors.
Datavault AI Appoints Christopher Hardt as Independent Director
Datavault AI Iannounced the appointment of Christopher Hardt to its board of directors as an independent director. Hardt was designated by NYIAX in connection with Datavault AI's recently completed acquisition and previously served on NYIAX's board of directors. He will also serve on the Audit Committee and Nominating and Corporate Governance Committee of the Company's board of directors.
Datavault AI Approves Rights Offering, Up to $50 Million Financing
Datavault AI announced that its board of directors has approved a rights offering to holders of its common stock and certain other Datavault AI securities. Moody Capital Solutions will act as dealer manager for the rights offering. Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distribution. The Company has set a record date of October 9 for such offering. Such holders will receive one subscription right for a Common Unit for each share of Common Stock owned as of the Record Date and one subscription right for a Preferred Unit for each 100 shares of Common Stock owned as of the Record Date. Common Units. Each Common Unit will consist of one share of Common Stock, one Series A Right to purchase one share of Common Stock and one Series B Right to purchase one share of Common Stock. The subscription price of each Common Unit will be $0.20. The Series A Right will be exercisable at $0.25 per share and will expire six months from the closing of the rights offering. The Series B Right will be exercisable at $0.30 per share and will expire twelve months from the closing. The Company expects to offer up to $50,000,000 of Common Unit subscription rights. Preferred Units. Each Preferred Unit will consist of one share of a newly designated series of preferred stock, one Series 1 Right to purchase one share of Preferred Stock and one Series 2 Right to purchase one share of Preferred Stock The subscription price of each Preferred Unit will be $25.00. The Series 1 Right will be exercisable at $30.00 per preferred share and will expire six months from the closing of the rights offering. The Series 2 Right will be exercisable at $35.00 per preferred share and will expire twelve months from the closing. The Preferred Stock will carry a stated value and liquidation preference of $25.00 per share and will rank senior to the Common Stock. It will pay a cumulative dividend of $2.10 per share per annum, payable semi-annually in arrears in cash, at the Company's election, in additional shares of the same series, or at the Company's election, in common stock at a 10% discount to market, subject to a floor price and an aggregate cap, as will be described in the prospectus supplement for the Rights Offering. The Company intends to apply to list the Preferred Stock on the Nasdaq Capital Market and to seek a listing or quotation for the Common Unit subscription rights, Preferred Unit subscription rights, Series A Rights, Series B Rights, Series 1 Rights and Series 2 Rights, although no assurance can be given that any listing will be obtained. The Preferred Stock will not be convertible into Common Stock. The Preferred Stock will vote together with the Common Stock as a single class on all matters submitted to a vote of stockholders, with the number of votes per preferred share to be fixed at execution of the dealer manager agreement by reference to the number of shares of Common Stock that $25.00 would then purchase. The Company expects to offer up to 3,000,000 Preferred Units, representing up to $75,000,000 of Preferred Unit subscription rights.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.